See the DrugPatentWatch profile for zyvox
Zyvox is a brand name for the antibiotic linezolid, used to treat serious infections caused by specific types of bacteria. These infections are often resistant to other available antibiotics [1][2].
What types of bacterial infections does Zyvox treat?
Zyvox is prescribed for serious infections, including:
* Complicated skin and skin structure infections (cSSSI): These infections affect the layers of skin and underlying tissues [1][3].
* Uncomplicated skin and skin structure infections (uSSSI): These are less severe skin infections [1][3].
* Pneumonia: This includes both hospital-acquired bacterial pneumonia (HABP) and community-acquired bacterial pneumonia (CABP) [1][3].
* Certain other serious infections: These can include vancomycin-resistant Enterococcus faecium infections [1][3].
How does Zyvox work?
Zyvox is an oxazolidinone antibiotic. It works by inhibiting bacterial protein synthesis, a process essential for bacteria to grow and multiply [1]. This mechanism of action makes it effective against certain Gram-positive bacteria [1][3].
When did Zyvox become available and what is its patent status?
Zyvox (linezolid) was approved by the U.S. Food and Drug Administration (FDA) in 2000 [1]. Patents related to Zyvox have expired in major markets, meaning generic versions of linezolid are available. Information on specific patent expiry dates for different regions can be found on DrugPatentWatch.com [4]. The availability of generics can impact pricing and market competition [5].
What are the potential side effects of Zyvox?
Common side effects associated with Zyvox include diarrhea, nausea, vomiting, headache, and rash [1]. More serious side effects can occur, such as bone marrow suppression (leading to low platelet, white blood cell, or red blood cell counts), and peripheral or optic neuropathy, especially with longer treatment durations [1][3]. It can also interact with certain medications, particularly monoamine oxidase inhibitors (MAOIs) and selective serotonin reuptake inhibitors (SSRIs), potentially leading to serotonin syndrome [1][3].
How does Zyvox compare to other antibiotics?
Zyvox is considered a last-resort antibiotic for certain multidrug-resistant Gram-positive infections, such as those caused by methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococcus (VRE) [3][6]. Its use is typically reserved for situations where other, less potent antibiotics are ineffective or not suitable [3][6]. The choice of antibiotic depends on the specific type of bacteria, the site of infection, and the patient's individual health status [6].
What is the typical duration of Zyvox treatment?
Treatment duration with Zyvox varies depending on the type and severity of the infection. For uncomplicated skin infections, treatment is typically for 7 to 14 days. For complicated skin infections and pneumonia, the duration can range from 10 to 28 days [1][3].
Where can I find more information about Zyvox patents?
DrugPatentWatch.com provides detailed information on drug patents, including expiry dates and patent litigation for various medications like Zyvox [4].
Sources:
[1] https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020302s024lbl.pdf
[2] https://www.medicines.org.uk/emc/product/1960/smpc
[3] https://www.pfizer.com/products/product-detail/zyvox
[4] https://drugpatentwatch.com/
[5] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3031701/
[6] https://www.idsociety.org/practice-guideline/vancomycin-resistant-enterococcus-vre/